Reference
This document was uploaded by user and they confirmed that they have the permission to share it. If you are author or own the copyright of this book, please report to us by using this DMCA report form. Report DMCA
Overview
Download & View Reference as PDF for free.
More details
- Words: 491
- Pages: 3
1.Early
Breast Cancer Trialists’Collaborative Group:Effects of chemotherapy and hormaonal therapy for early breast cancer on recurrence and 15 yrear survival:An overview of the randomized trials.Lancet 2005;1687-1717. 2.Fisher B,Costantino JP,Wickerham DL,Redmond CK,Kavanah M,Cronin WM,et al. Tamoxifen for prevention of breast cancer :report of the National Surgical Adjuvant Breast and Bowel project P-1 study. J Natl Cancer Inst 1998;90:1371-88 3.Osborne CK.Tamoxifen in the treatment of breast cancer .N Eng J Med 1998;339:1609-18 4.Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival:An overview of the randomized trials .Lancet 365:16871717,2005 5.Early Breast Cancer Trialist’s Collaborative Group ( EBCTCG): Tamoxifen for early breast cancer : an overview of the randomisedtrials.Lancet 1998:1451-1467. 6.Coezy E,Borgna J-L,Roachefort H : Tamoxifen and metabolites in MCF7 cells :correlation between binding to estrogen receptorand inhibition of cell growth.Cancer Res 1982, 42:317-323. 7.Dehal SS,Kupfer D : CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver.Cancer Res 1997,57:34 8.Boocock DJ,Brown K, Gibbs AH,Sanchez E,Turteltaub KW,White INH : Identification of CYP forms involve tamoxifen and irreversible binding to DNA.Carcubigebesus 2002,23:1897-1901. 9.Fabian C,Tilzer L,Sternson L : Comparative binding affinities of tamoxifen,4hydroxytamoxifen,and desmethyltamoxifen for estrogen receptor isolated from human breast carcinoma : correlation with blood levels in patients with metastatic breast cancer.Biopharma Drug Dispos 1981,2:381-390. 10.Nolvadex (Tamoxifen citrate ) label.9-27-2005.Wilmington,Delaware,AstraZeneca Pharmaceuticals LP.
11.Lien EA,Solheim E,Lea OA, et al : Distribution of 4-hydroxy-Ndesmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment.Cancer Res 49:2175-2183,1989. 12.Lien EA,Anker G,Lonning PE, et al : Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide.Cancer Res 50:5851-5857,1990. 13.Lien EA,Solheim E,Ueland PM : Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res 51:4837-4844,1991. 14.Stearns V,Johnson MD , Rae JM, et al : Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95 :1758-1764,2003. 15.Jin Y,Desta Z,Stearns V, et al :CYP2D6 genotype,antidepressant use,and tamoxifen metabolism during adjuvant breast cancer treatment.J Natl Cancer Inst 97:30-39,2005. 16.Goetz MP,Rae JM,Suman VJ,Safgren SL,Ames MM,Visscher DW et al.Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.J clin Oncol.Dec,23(36)9312-8 (2005). 17.Knox SK,Ingle JN,Suman VJ,Rae JM,Flockhart DA,Zeruesenay D et al. Cytochrome P450 2D6 status predicts breast cancer relapse in women receiving adjuvant tamoxifen(Tam).J Clin Oncol.24,4s (2006).
18.Stearns V,Johnson MD,Rae JM,Morocho A,Novielli A,Bhargava P,et al.Active tamoxifen metabolite plasma concentration after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.J Natl Cancer Inst 2003;95:175864.4s (2006). 19.Laurent Bodin,Philippe H.Beaune,Marie-Anne Loriot et al.Determination of Cytochrome P450 2D6(CYP2D6)Gene Copy Number by real time Quantitaive PCR.J of biomedicine and biotechnology2005:3(2005)248-253.
20.Stefan Kropp,Ralf Lichtinghagen,Kathrin Winterstein,Jann Schlimme,Udo Schnelider et al.Cytochrome P-450 2D6 and 2C19 Polymorphsims and length of hospitalization in psychiatry.J Clin Lab.2006;52:237-240. 21.Ulrike M.Stamer,Bettina Bayerer,Stephanie Wolf et al.Rapid and reliable method for cytochrome p4502D6 genotyping.J clinical chemistry 48:9 (2002)1412-1417. 22.Bernado Bonanni,Debora Macis,Patrick Maisonneuve et al.Polymorphism in the CYP2D6 Tamoxifen-metabolizing gene influences clinical effect but not hot flash :Data from the Italian tamoxifen trial. J clin Oncol.Nov,24(22)3708.
Breast Cancer Trialists’Collaborative Group:Effects of chemotherapy and hormaonal therapy for early breast cancer on recurrence and 15 yrear survival:An overview of the randomized trials.Lancet 2005;1687-1717. 2.Fisher B,Costantino JP,Wickerham DL,Redmond CK,Kavanah M,Cronin WM,et al. Tamoxifen for prevention of breast cancer :report of the National Surgical Adjuvant Breast and Bowel project P-1 study. J Natl Cancer Inst 1998;90:1371-88 3.Osborne CK.Tamoxifen in the treatment of breast cancer .N Eng J Med 1998;339:1609-18 4.Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival:An overview of the randomized trials .Lancet 365:16871717,2005 5.Early Breast Cancer Trialist’s Collaborative Group ( EBCTCG): Tamoxifen for early breast cancer : an overview of the randomisedtrials.Lancet 1998:1451-1467. 6.Coezy E,Borgna J-L,Roachefort H : Tamoxifen and metabolites in MCF7 cells :correlation between binding to estrogen receptorand inhibition of cell growth.Cancer Res 1982, 42:317-323. 7.Dehal SS,Kupfer D : CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver.Cancer Res 1997,57:34 8.Boocock DJ,Brown K, Gibbs AH,Sanchez E,Turteltaub KW,White INH : Identification of CYP forms involve tamoxifen and irreversible binding to DNA.Carcubigebesus 2002,23:1897-1901. 9.Fabian C,Tilzer L,Sternson L : Comparative binding affinities of tamoxifen,4hydroxytamoxifen,and desmethyltamoxifen for estrogen receptor isolated from human breast carcinoma : correlation with blood levels in patients with metastatic breast cancer.Biopharma Drug Dispos 1981,2:381-390. 10.Nolvadex (Tamoxifen citrate ) label.9-27-2005.Wilmington,Delaware,AstraZeneca Pharmaceuticals LP.
11.Lien EA,Solheim E,Lea OA, et al : Distribution of 4-hydroxy-Ndesmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment.Cancer Res 49:2175-2183,1989. 12.Lien EA,Anker G,Lonning PE, et al : Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide.Cancer Res 50:5851-5857,1990. 13.Lien EA,Solheim E,Ueland PM : Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res 51:4837-4844,1991. 14.Stearns V,Johnson MD , Rae JM, et al : Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95 :1758-1764,2003. 15.Jin Y,Desta Z,Stearns V, et al :CYP2D6 genotype,antidepressant use,and tamoxifen metabolism during adjuvant breast cancer treatment.J Natl Cancer Inst 97:30-39,2005. 16.Goetz MP,Rae JM,Suman VJ,Safgren SL,Ames MM,Visscher DW et al.Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.J clin Oncol.Dec,23(36)9312-8 (2005). 17.Knox SK,Ingle JN,Suman VJ,Rae JM,Flockhart DA,Zeruesenay D et al. Cytochrome P450 2D6 status predicts breast cancer relapse in women receiving adjuvant tamoxifen(Tam).J Clin Oncol.24,4s (2006).
18.Stearns V,Johnson MD,Rae JM,Morocho A,Novielli A,Bhargava P,et al.Active tamoxifen metabolite plasma concentration after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.J Natl Cancer Inst 2003;95:175864.4s (2006). 19.Laurent Bodin,Philippe H.Beaune,Marie-Anne Loriot et al.Determination of Cytochrome P450 2D6(CYP2D6)Gene Copy Number by real time Quantitaive PCR.J of biomedicine and biotechnology2005:3(2005)248-253.
20.Stefan Kropp,Ralf Lichtinghagen,Kathrin Winterstein,Jann Schlimme,Udo Schnelider et al.Cytochrome P-450 2D6 and 2C19 Polymorphsims and length of hospitalization in psychiatry.J Clin Lab.2006;52:237-240. 21.Ulrike M.Stamer,Bettina Bayerer,Stephanie Wolf et al.Rapid and reliable method for cytochrome p4502D6 genotyping.J clinical chemistry 48:9 (2002)1412-1417. 22.Bernado Bonanni,Debora Macis,Patrick Maisonneuve et al.Polymorphism in the CYP2D6 Tamoxifen-metabolizing gene influences clinical effect but not hot flash :Data from the Italian tamoxifen trial. J clin Oncol.Nov,24(22)3708.
